RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the details of the Analyst/ Institutional Investors meet which will be participated by the Company along with the presentation to be made at the same. RPG LIFE SCIENCES LTD. - 532983 - Communication To Shareholders
This is to inform you that the Company has dispatched requisite communication to physical shareholders requesting them to update/furnish prescribed details related to KYC with the Registrar and Share Transfer Agent of the Company viz., Link Intime India Private Limited, pursuant to SEBI Circular dated November 03, 2021 and December 14, 2021. The communication and requisite Forms are also available on the website of the Company at below link: https://www.rpglifesciences.com/website/kyc_for_physical_shares.php Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith intimation of loss of share certificate as received by us from Link Intime Private Limited, our Registrar and Share Transfer Agent, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Unaudited Financial Results for the quarter and nine months ended December 31, 2021. Kindly take this information on record. Q3FY22 Quarterly Result Announced for RPG Life Sciences Ltd.
Pharmaceuticals company RPG Life Sciences declares Q3FY22 result: 9M FY22 Revenue from operations grew by 13% and PBT grew by 39% with EBITDA margin expanding from 19.5% to 22.2% YoY RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 21% YoY for Q3 FY22, maintaining the upward trajectory in EBITDA margins, which improved from 19.9% to 21.4% YoY. Revenue from operations at Rs 115.58 crores registered a growth of 7% YoY for Q3 FY22. For 9M FY22, the company posted a jump in PBT by 39% YoY and recorded EBITDA margin expansion from 19.5% to 22.2% YoY. Revenue from operations at Rs 336.36 crores registered a growth of 13% YoY for 9M FY22. Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “I am pleased to share that in Q3 FY22, we continued to deliver a robust performance. Revenue and PBT grew by 7% and 21% respectively YoY. EBITDA margins’ upward trajectory continued, growing from 19.9% to 21.4% YoY. The Company continues to remain debt free with highest-ever net cashflow generated from operations in 9M FY22. Domestic Formulations business recorded a robust growth both in value and volumes - significantly better than the market. While life cycle management initiatives helped legacy brands register healthy growth, our new product portfolio is also witnessing an impressive uptake. We have successfully forayed into a new segment - Rheumatology, which is strengthening our endeavour of expanding into the Specialty segment. Salesforce productivity continues to register upward momentum. API business also recorded robust growth. In the International Formulations business, our growth was somewhat subdued due to the political unrest in one of our key markets, Myanmar. However, rest of the international business reflected strong performance supported by new launches. Going forward, we stay committed to implementing our Transformation Agenda to grow both topline and bottomline across segments.” Result PDF
RPG Life Sciences net profit rises 14% at Rs 15 crore in third quarter
RPG Life Sciences said its net profit increased 14 per cent to Rs 14.63 crore for the third quarter ended December 31, 2021. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021. Kindly take the above on record. RPG LIFE SCIENCES LTD. - 532983 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2021
Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter and nine months ended December 31, 2021 which were approved by the Board of Directors of the Company, at its meeting held on January 25, 2022 along with Limited Review Report issued by the Statutory Auditors of the Company. The meeting commenced at 03:00 p.m. and concluded at 05:15 p.m. Kindly take the above on record. RPG LIFE SCIENCES LTD. - 532983 - Board Meeting Outcome for Outcome Of Board Meeting
In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has at its meeting held on Tuesday, January 25, 2022, inter-alia, considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021, along with Limited Review Report of the Statutory Auditors thereon. The meeting commenced at 03:00 p.m. and concluded at 05:15 p.m. Kindly take the above on record.